• Study of varlitinib for first-line gastric cancer treatment misses primary endpoint

    One year ago - By Healio

    A phase 2 study designed to compare varlitinib with placebo as first-line treatment for certain patients with gastric cancer failed to meet its primary endpoint of significant reduction in tumor size after 12 weeks of treatment.
    Varlitinib is an oral, reversible, small molecule pan-HER inhibitor that targets HER1, HER2 and HER4. The agent is under investigation as treatment for gastric, biliary tract, breast and colorectal cancers.
    ASLAN conducted a placebo-controlled, double-blind study to compare modified FOLFOX6 chemotherapy - which consists of
    Read more ...